Inozyme Pharma (INZY) Stock Analysis

What Inozyme Pharma does

Inozyme Pharma, Inc. operates as a biopharmaceutical entity dedicated to addressing rare diseases. Its primary mission involves pioneering treatments for disorders characterized by aberrant mineralization, which impacts the body's vascular system, soft tissues, and skeletal structure. The company's flagship therapeutic candidate, INZ-701, is an engineered, soluble protein under development to combat specific genetic conditions, namely ENPP1 and ABCC6 deficiencies, as well as for the management of calciphylaxis. Inozyme maintains a licensing arrangement with Yale University concerning particular therapeutic and preventative agents. Established in 2015, the firm's main offices are situated in Boston, Massachusetts.

Key metrics

ETFs linked to INZY

Broad-market and Healthcare sector ETFs an investor holding Inozyme Pharma is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how INZY fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Inozyme Pharma?

Inozyme Pharma trades under the ticker INZY on NASDAQ.

Which exchange is INZY listed on?

INZY is listed on NASDAQ.

What sector does Inozyme Pharma operate in?

Inozyme Pharma is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze INZY in a portfolio?

PortView shows INZY's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.